u/freya_baptista

research-use-only labelling is not a customs category

Asked CPC which lines they hold regionally before ordering and got a straight list back. Changed what I ordered and when.

It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it.

phase 2 data only, and people quote it like it is a label

What did system suitability look like on that sequence?

That is body weight change, not fat mass.

Agreed, and the glucagon arm is exactly why the comparison threads do not work.

a shoulder is not an impurity until you can resolve it

Increases in heart rate have been reported across this receptor class. The magnitude and clinical significance are exactly what phase 3 is powered to establish.

Yes. Week 19 is when almost everybody writes the "is it still working" post, and almost everybody is fine.

reship policy in writing before you order

I would not blame the sample yet. Everything you have described is consistent with the column rather than the vial.

a quoted lead time you can hold them to is worth more than a fast one you cannot

Same view — reporting the gradient is what makes a result checkable rather than merely stated.

UV response is not uniform across species. At 214nm you are looking at the peptide bond, which is why it is the working wavelength for this class; at 280nm you only see tryptophan, tyrosine and phenylalanine.

Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use, and that is a statement of fact rather than a disclaimer.

Nothing on this board is legal advice. Where a notice carries a deadline or a consequence, that is a matter for somebody qualified in your own jurisdiction.

Kept a log from week one and the single most useful column turned out to be waist, not weight.

Batch number and date of analysis, are both on there?

I would push back gently. Going up because the scale paused is the single most common mistake described on this board.

Area percent is the integrated area of your peak over the total integrated area at one wavelength on one gradient. Change any of those and the number changes without the sample changing.

the phase 2 numbers were striking and they were also 48 weeks in a small population

Mass spectrometry answers identity. UV purity answers relative quantity under the run conditions. A document with one and not the other is answering half the question, and the half it answers should be stated.

STEP-1 ran 68 weeks and landed just under 15% mean body weight change on 2.4mg. It is an average of a wide distribution, not a target you have missed.

Are you comparing against phase 3 numbers for something else? They are not comparable.

Not convinced.

Disagree with this specific line. A pause at 1.0mg is not evidence that 1.0mg has stopped working.

ApoB is the one worth adding if you only add one

Same lane in a different season for comparison?

nothing here is available as a prescription product, so read every thread with that in mind

area percent is relative to what the detector saw and nothing else

Which phase 2 arm are you quoting, and at what week?

Batch number and date of analysis, are both on there?

A shoulder that does not baseline-resolve cannot be quantified honestly. You can report it as an unresolved shoulder, which is useful information, or you can develop the method until it resolves.

you cannot report to two decimals off that baseline

Careful — "the metadata looks odd" is a reason to ask a question, not a conclusion. Re-issues are ordinary.

the first four weeks are a tolerance check, not a weight-loss phase

This is the part I would underline for anyone skimming. Everything else in the thread is downstream of it.

This. Area percent answers "what fraction of what the detector saw was the peak I wanted", and people read it as "how much peptide is in the vial".

A lane is an origin, a destination, a carrier and a season. Change any one and the distribution changes, which is why supplier-level shipping averages are close to meaningless.

What did the repeat show?

the escalation is where most of the reported trouble sits

Agreed on rigid packaging. It costs the shipper almost nothing and it predicts a lot about the rest of the operation.